Jerusalem, 11 November, 2026 (TPS-IL) — Israeli biopharma company LifeBiotic has launched a randomized Phase 2 clinical trial at Rambam Health Care Campus in Haifa to assess whether a botanical drug candidate can help prevent bladder cancer recurrence. The 60-patient trial will evaluate the safety and effectiveness of LCS103, an oral formulation combining plant-derived ingredients, alongside standard treatment.
The study follows a 2024 published case series involving 20 patients, which found that the proportion experiencing recurrence fell from 55% before treatment to 15% after starting LCS103. Researchers will now test those preliminary findings in a controlled trial, examining cancer recurrence, safety and patients’ quality of life.
